Gregory DJ, KobzikL.
Am J Physiol Lung Cell Mol Physiol. 2015Nov 15;309(10):L1041-6. doi: 10.1152/ajplung.00283.2015. Epub 2015Sep 25. Review.
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.